Related Experiment Videos
Anti-CD30 immunotoxins with native and recombinant dianthin 30
A Bolognesi1, P L Tazzari, G Legname
1Dipartimento di Patologia sperimentale dell'Università di Bologna, Italy.
Cancer Immunology, Immunotherapy : CII
|February 1, 1995
Summary
New immunotoxins targeting CD30+ cancer cells show potent protein synthesis inhibition. Recombinant dianthin 30 immunotoxins are highly effective against Hodgkin
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Monoclonal antibodies are crucial for targeted cancer therapies.
- Ribosome-inactivating proteins (RIPs) can be used as cytotoxic payloads.
- CD30 is a validated target in certain hematologic malignancies.
Purpose of the Study:
- To develop and evaluate immunotoxins targeting the CD30 antigen.
- To assess the efficacy of native and recombinant dianthin 30-based immunotoxins.
- To determine the protein synthesis inhibitory activity against CD30+ cancer cell lines.
Main Methods:
- Preparation of immunotoxins using Ber-H2 (anti-CD30) antibody and dianthin 30 (native and recombinant).
- Testing protein synthesis inhibition in CD30+ cell lines (D430B, L428, L540, K562).
- Determination of IC50 values for dianthin 30 and the immunotoxins.
Main Results:
- Both immunotoxins selectively inhibited protein synthesis in CD30+ cell lines D430B, L428, and L540.
- Immunotoxins with recombinant dianthin 30 exhibited higher potency (45–182 pM IC50) compared to native dianthin 30 (324–479 pM IC50).
- No significant difference in protein synthesis inhibition was observed for the CD30+ K562 cell line compared to free dianthin.
Conclusions:
- Immunotoxins combining Ber-H2 and dianthin 30 are effective against CD30+ lymphoma cell lines.
- Recombinant dianthin 30 demonstrates superior potency in immunotoxin applications.
- These findings support the potential of CD30-targeted immunotoxins for cancer therapy.